Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864054 · ClinicalTrials.gov registry record · Phase 1
T-Cell Therapy (ECT204) in Adults With Advanced HCC
A Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult, sponsored by Eureka Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT04864054: Recruiting Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult, sponsored by Eureka Therapeutics.
NCT04864054 is a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult that is actively recruiting participants, run by Eureka Therapeutics. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04864054, a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult, is actively recruiting participants, sponsored by Eureka Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.
Primary Outcome
Type, frequency, and severity of adverse events (AEs), including treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), clinically significant laboratory abnormalities recorded as AEs, and AEs leading to permanent discontinuation.
Conditions Studied
Interventions
- BIOLOGICAL ECT204 T cells
Study Locations (7)
California
- City of Hope - Duarte
Kansas
- Kansas University Medical Center, Principal Investigator: - Westwood
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Oregon
- Oregon Health and Sciences University - Portland
Texas
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center - Dallas
Washington
- Fred Hutchinson Cancer Center, University of Washington - Seattle
Other
- National Taiwan University Cancer Center - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT04864054 shows while recruiting
NCT04864054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ECT204 T cells is the first listed.
NCT04864054 lists 7 locations in 7 states (California, Kansas, New York).
Frequently Asked Questions
What is clinical trial NCT04864054 about?
NCT04864054 is a clinical study titled "T-Cell Therapy (ECT204) in Adults With Advanced HCC". This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed ...
What is the current status of trial NCT04864054?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-03-11. Estimated completion is 2027-12-31.
What conditions does trial NCT04864054 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer.
What interventions are being tested in trial NCT04864054?
The interventions under investigation include: ECT204 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04864054?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04864054 being conducted?
This trial has 7 study locations across California, Kansas, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04864054's enrollment target sits among peer trials
20 123rd of 145 higher than 16 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI